Department of Interventional Radiology, The Fourth Medical Centre, Chinese PLA (People's Liberation Army), Beijing 100089, China.
Department of Interventional Radiology, The Third Affiliated Hospital of Harbin Medical University, Harbin 150000, China.
Recent Pat Anticancer Drug Discov. 2021;16(3):312-332. doi: 10.2174/1574892816666210208231744.
Camrelizumab, which was launched in China on May 29, 2019, is a humanized anti-programmed cell death-1 (PD-1) antibody. It is used for the treatment of complicated or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy. On March 4, 2020, camrelizumab was approved as a second-line drug in China for the treatment of advanced hepatocellular carcinoma. Currently, camrelizumab is undergoing clinical research for advanced solid tumors such as liver cancer, gastric cancer, esophageal cancer, and lung cancer, and all have shown clinical efficacy.
This review describes preclinical studies on camrelizumab and its efficacy and safety in clinical studies in various tumors.
A literature search was conducted on basic research and clinical trials of camrelizumab determined its pharmacology, toxicology, pharmacokinetic properties, and current clinical research status. We also analyzed the difference between camrelizumab and other PD-1 antibodies.
The results of preclinical studies show that camrelizumab binds to the PD-1 receptor and has stable anti-tumor activity in a dose-dependent manner. Clinical studies show that camrelizumab has therapeutic effects on a variety of tumors. The incidence of adverse reactions with camrelizumab is low, with most being mild, reversible, and predictable.
This review summarizes the current status of preclinical and clinical studies on camrelizumab. Current research confirms that camrelizumab alone or in combination with other drugs shows significant anti-cancer activity and a low incidence of adverse reactions. However, further studies are needed to verify the application potential of camrelizumab in a variety of tumors.
卡瑞利珠单抗于 2019 年 5 月 29 日在中国上市，是一种人源化抗程序性细胞死亡蛋白-1（PD-1）抗体。用于治疗至少二线化疗后复发或难治性经典霍奇金淋巴瘤。2020 年 3 月 4 日，卡瑞利珠单抗在中国被批准用于二线治疗晚期肝细胞癌。目前，卡瑞利珠单抗正在进行肝癌、胃癌、食管癌和肺癌等晚期实体瘤的临床研究，均显示出临床疗效。
本综述描述了卡瑞利珠单抗的临床前研究及其在各种肿瘤的临床研究中的疗效和安全性。
通过文献检索，确定了卡瑞利珠单抗的基础研究和临床试验，描述了其药理学、毒理学、药代动力学特性和目前的临床研究现状。还分析了卡瑞利珠单抗与其他 PD-1 抗体的差异。
临床前研究结果表明，卡瑞利珠单抗与 PD-1 受体结合，具有剂量依赖性的稳定抗肿瘤活性。临床研究表明，卡瑞利珠单抗对多种肿瘤均有治疗作用。卡瑞利珠单抗不良反应发生率低，多为轻度、可逆、可预测。
本综述总结了卡瑞利珠单抗的临床前和临床研究现状。目前的研究证实，卡瑞利珠单抗单独或与其他药物联合使用具有显著的抗癌活性，不良反应发生率低。然而，还需要进一步的研究来验证卡瑞利珠单抗在多种肿瘤中的应用潜力。
